<sup>68</sup>Ga-FAPI PET/CT as an Alternative to<sup>18</sup>F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma
Ertan Şahin, Tülay Kuş, Alper Aytekin, Evren Uzun, Umut Elboğa, Latif Yılmaz, Yusuf Burak Çayırlı, Merve Okuyan, Vuslat Mumcu ÇİMEN, Ufuk Çimen
Abstract
Accurate staging of invasive lobular carcinoma (ILC), a subtype of breast cancer, is vital for effective clinical management. Although <sup>18</sup>F-FDG PET/CT is a commonly used tool, its efficacy varies across different histologic subtypes. To mitigate this challenge, our investigation delves into the potential utility of <sup>68</sup>Ga-fibroblast activation protein inhibitor (FAPI) PET/CT as an alternative for staging ILC, aiming to address a significant research gap using a more expansive patient cohort than the smaller samples commonly found in the existing literature. <b>Methods:</b> In this retrospective analysis, women diagnosed with primary ILC of the breast underwent both <sup>18</sup>F-FDG PET/CT and <sup>68</sup>Ga-FAPI PET/CT. Both modalities were compared across all lesion locations with the used reference standard. The interval between scans was 1 wk, without any intervening treatments. Lesions were categorized visually, and tracer activity was analyzed using SUV<sub>max</sub>, tumor-to-background uptake ratio, and uptake ratios. Both modalities were compared across various parameters, and statistical analysis was performed using SPSS 22.0. A <i>P</i> value of less than 0.05 was chosen to determine statistical significance. <b>Results:</b> The study included 23 female ILC patients (mean age, 51 y) with hormone-positive, human epidermal growth factor receptor type 2–negative tumors. Most (65%) had the luminal A subtype. <sup>68</sup>Ga-FAPI PET/CT outperformed <sup>18</sup>F-FDG PET/CT, with higher tumoral activity and tumor-to-background uptake ratios (<i>P</i> < 0.001). Primary tumors showed significantly increased uptake with <sup>68</sup>Ga-FAPI PET/CT (<i>P</i> < 0.001), detecting additional foci, including multicentric cancer. Axillary lymph node metastases were more frequent and had higher uptake values with <sup>68</sup>Ga-FAPI PET/CT (<i>P</i> = 0.012). Moreover, <sup>68</sup>Ga-FAPI PET/CT identified more lesions, including bone and liver metastases. Pathologic features did not significantly correlate with imaging modalities, but a positive correlation was observed between peritumoral lymphocyte ratio and <sup>68</sup>Ga-FAPI PET/CT–to–<sup>18</sup>F-FDG PET/CT uptake ratios (<i>P</i> = 0.026). <b>Conclusion:</b> This study underscores <sup>68</sup>Ga-FAPI PET/CT’s superiority over <sup>18</sup>F-FDG PET/CT for ILC. <sup>68</sup>Ga-FAPI PET/CT excels in detecting primary breast masses, axillary lymph nodes, and distant metastases; can complement <sup>18</sup>F-FDG PET/CT in ILC; and holds potential as an alternative imaging method in future studies.